Epithelioid Sarcoma Target & Drug Identification: $120,000 annually

Crowdfunded in large part by the Epithelioid Sarcoma Community, and in need of ongoing funding!

Epithelioid Sarcoma (EPS) is a very rare soft tissue of children and adults.  The underlying clinical problem is that only surgery is curative: chemotherapy and radiation are ineffective.  Late relapse with metastases results in a significant unmet clinical need because surgery is not possible and effective targeted therapies have not yet been developed – until recently.  Now, an EZH2 inhibitor named Tazemetostat offers responses and disease control for months at a time.  The next step of our program with international collaborators is to find the type of treatments that complement Tazemetostat.